Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

NDAQ:LMNL - Post Discussion

Liminal BioSciences Inc. > why would a company sell its plasma division for peanuts
View:
Post by edrose on Sep 16, 2021 7:47am

why would a company sell its plasma division for peanuts

two weeks before fda approval     plasma fractionation is a multi billion dollar business and prometics patented tech  proven to be safe and more efficient than the old cohns process

this will come out during discovery under oath
Comment by Damnre on Sep 16, 2021 1:53pm
actuallly they paid 30million so they take it!!
Comment by GunnerG on Sep 16, 2021 9:32pm
Kedrion never paid $30 M for the plasma. LMNL got 17M for the two plasma facilities and 5M for Ryplazim and the fractionation business. LMNL gave $30M of the PRV sale to Kedrion. Two weeks before FDA approval.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities